Akebia Therapeutics (AKBA) Tops Q1 EPS by 15c

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.47), $0.15 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $88.5 million versus the consensus estimate of $77.48 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• Infleqtion raises Q2 revenue to $13.5M after contract restatement